The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While https://miriamdmtu518380.howeweb.com/39730301/glp-3-retatrutide-a-comparative-analysis